LID.L Regulatory News (LID)

LiDCO Group Plc

("LiDCO" or the "Company")

Further clinical support for LiDCO products

New nurse-led study shows the benefits of haemodynamic optimisation using LiDCOplus

LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, announces that a new prospective observational trial covering a total of 264 cardiac surgery patients has been accepted for publication in the next edition of the Journal of Critical Care*. The study showed that the use of LiDCOplus significantly reduced the incidence of acute kidney injury (AKI), reduced the subsequent need for renal replacement therapy, and reduced the hospital length of stay.

Details of the study

The active treatment arm had post-operative stroke volume maximisation using the LiDCOplus which was compared to a treatment arm using standard of care.

The study evaluated the outcome of 123 cardiac surgery patients who had post-operative stroke volume maximisation Goal-Directed Therapy (GDT) using the LiDCOplus compared to 141 patients who had standard post-operative monitoring. The patients all had coronary artery bypass with or without aortic valve surgery. Importantly the intervention was nurse led in the cardiac intensive care unit (ICU) and consisted of fluid challenges to maximise stroke volume over an 8 hour period following admission to the ICU.

Although both groups received similar volumes of fluid, the authors agreed that the GDT group received the fluids earlier before haemodynamic compromise was observed in contrast to the control group who received fluids after signs of haemodynamic compromise. Importantly the incidence of AKI was significantly reduced in the GDT group with a total of 8 patients (6.5%) exhibiting AKI compared to 28 (19.9%) in the standard of care group. The median duration of hospital stay was 6 days in the GDT group compared to 7 days patients receiving standard of care.

The investigators also report that the GDT group had a low (3.3%) requirement for renal replacement therapy (RRT dialysis) compared to 10.6% in the standard of care group. In addition, the rate of readmissions to the ICU was reduced in the GDT group.

Commenting, Terry O'Brien, Chief Executive Officer of LiDCO, said: "This is an important study in a cardiac group of patients where the incidence of AKI is high averaging around 24%. AKI is associated with a high mortality rate of 7% - so avoiding it is very worthwhile clinically. Financially, the number of inpatients affected by AKI means that it has a major impact on healthcare resources. NICE (National Institute for Health and Care Excellence) has estimated that the costs to the NHS of AKI (excluding costs in the community) are between £434m and £620m per year, which is more than the costs associated with breast cancer, or lung and skin cancer combined*. The study clearly shows that avoidance of kidney compromise through using the LiDCO's fluid monitoring technology overseen by the ICU nursing team can reduce the incidence of post-operative AKI by 70%, which represents a significant saving to the NHS and improves patient outcomes."

· Thomson Rebekah, Meeran Hanif, Valencia Oswaldo, Al-Subaie Nawaf, Goal-Directed therapy following cardiac surgery and the incidence of acute kidney injury, Journal of Critical Care (2014), doi: 10.1016/j.jcrc.2014.06.011

· NICE Guidance CG169 Aug 2013: http://www.nice.org.uk/guidance/CG169/chapter/introduction

About LiDCO Group Plc (www.lidco.com)

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre. 

Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

Key Products:

LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%).

LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides:

· early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug

· quantification of hemodynamic response

· guidance on effective delivery of fluids to ensure the right amount at the right time

LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.

LiDCO Unity Software: software incorporated into LiDCOrapid v2 that allows the LiDCOrapid monitor to co-display Covidien's level of consciousness parameter ('BISTM')* and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This will address a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors. 

*BISTM and Bispectral Index are trademarks of Covidien LP registered in the US and foreign countries.

* CNAPTM is a trademark of CNSystems Medizintechnik AG.

LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.

LiDCO Distribution Network:

LiDCO sells directly to hospitals in the UK and USA and through a network of specialty critical care and anaesthesia distributors in the rest of the world.

LiDCO's marketing office is in Cambridge, its manufacturing facility and headquarters are in London and its shares are traded on AIM.